LTZ Therapeutics ('LTZ'), an immunotherapy-focused biotechnology company, today announced a strategic research collaboration with Eli Lilly and Company ('Lilly') to develop novel myeloid engager therapeutics against selected targets for the treatment of diseases with high unmet need.

LTZ Therapeutics（“LTZ”），一家专注于免疫疗法的生物技术公司，今天宣布与Eli Lilly and Company（“Lilly”）达成战略研究合作，开发针对选定靶点的新型髓系结合治疗药物，用于治疗具有高度未满足需求的疾病。

Under the terms of the agreement, LTZ will receive a double-digit million USD upfront payment and an equity investment in the company. LTZ is also eligible to receive preclinical, clinical, regulatory and commercial milestone payments, in addition to tiered royalties on net sales of any resulting commercialized products..

根据协议条款，LTZ将获得一笔八位数的美元预付款以及对该公司的股权投资。此外，LTZ还有资格获得临床前、临床、监管和商业化的里程碑付款，以及任何商业化产品净销售额的阶梯式专利使用费。

'We are thrilled to enter into a strategic partnership with Lilly, a global leader in immunology and oncology,' said Robert Li, Founder and CEO of LTZ. 'This collaboration represents a pivotal step towards our mission in harnessing the potential of myeloid biology to address diseases with high unmet need.

“我们非常高兴能与免疫学和肿瘤学的全球领导者礼来公司建立战略合作伙伴关系，”LTZ创始人兼首席执行官李罗伯特表示。“此次合作标志着我们在利用髓系生物学潜力解决高度未满足需求的疾病方面迈出了关键一步。”

With Lilly's expertise and global reach, we're accelerating the development of our myeloid engager programs and we’re one step closer to bringing transformative therapies to the patients who need them most.'.

凭借礼来公司的专业技术和全球影响力，我们正在加速推进我们的髓系细胞接合器项目，距离为最需要的患者带来变革性疗法又近了一步。

About LTZ

关于LTZ

LTZ Therapeutics is an immunotherapy-focused biotechnology company pursuing the development of novel therapies, with the company's novel Myeloid Engager Platform, to improve clinical outcomes in patients with cancer and autoimmune diseases. With main operations in Redwood City, California and Shenzhen China as well as a team out of Heidelberg Germany, LTZ is dedicated to developing myeloid engager immunotherapies for broad disease indications.

LTZ Therapeutics是一家专注于免疫疗法的生物技术公司，致力于开发新型疗法，利用公司创新的髓系细胞接合平台（Myeloid Engager Platform）来改善癌症和自身免疫疾病患者的临床结果。公司主要运营地点位于美国加利福尼亚州红木城和中国深圳，并在德国海德堡设有团队，LTZ专注于为广泛的疾病适应症开发髓系细胞接合免疫疗法。

For more information, please visit https://www.ltztherapeutics.com/..

如需更多信息，请访问 https://www.ltztherapeutics.com/。

Media Contact:

媒体联系人：

Betsy Levy

贝琪·列维

betsy.levy@ltztherapeutics.com

贝琪·莱维@LTZ治疗学.com

415-377-3112

415-377-3112

Source: ltztherapeutics.com

来源：ltztherapeutics.com